Catalyst Pharmaceuticals (CPRX) EBIT Margin (2018 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly EBIT Margin came in at 49.02% in Q1 2026, up 421.0% YoY from 9.41% in Q1 2025, and up 20.96% on a QoQ basis from 40.52% in Q4 2025.
Powered by 
Analysis
Catalyst Pharmaceuticals (CPRX) EBIT Margin (2018 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 9 years of EBIT Margin data on file, last reported at 49.02% in Q1 2026.
- Quarterly EBIT Margin rose 421.0% year-over-year to 49.02% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 44.83% (up 156.0% YoY) and the FY2025 annual result came in at 43.77%, up 409.0% from the prior year.
- EBIT Margin climbed to 49.02% in Q1 2026, from 40.52% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 53.79% in Q2 2022 to a low of 36.21% in Q3 2023.
- A 5-year average of 38.74% and a median of 44.21% in 2024 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2023 — EBIT Margin sank 8007 bps — and 2024, when it surged 7577 bps.
- Tracing CPRX's EBIT Margin over 5 years: stood at 50.7% in 2022, then dropped by 26 bps to 37.71% in 2023, then rose by 18 bps to 44.31% in 2024, then fell by 9 bps to 40.52% in 2025, then gained by 21 bps to 49.02% in 2026.
- The last three EBIT Margin figures came in at 49.02% (Q1 2026), 40.52% (Q4 2025), and 44.66% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 49.02% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 49.02% |
| Dec 31, 2025 | 40.52% |
| Sep 30, 2025 | 44.66% |
| Jun 30, 2025 | 45.24% |
| Mar 31, 2025 | 44.81% |
| Dec 31, 2024 | 44.31% |
| Sep 30, 2024 | 39.56% |
| Jun 30, 2024 | 44.21% |
| Mar 31, 2024 | 27.54% |
| Dec 31, 2023 | 37.71% |
| Sep 30, 2023 | -36.21% |
| Jun 30, 2023 | 46.90% |
| Mar 31, 2023 | 41.71% |
| Dec 31, 2022 | 50.70% |
| Sep 30, 2022 | 43.85% |
| Jun 30, 2022 | 53.79% |
| Mar 31, 2022 | 40.30% |
| Dec 31, 2021 | 33.26% |
| Sep 30, 2021 | 38.95% |
| Jun 30, 2021 | 43.55% |